

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of  
**Jockers et al.**

Examiner: N/A

Art Unit: N/A

Application No.: 10/774,721

Filed: February 9, 2004

Title: **Oligonucleotides Which Inhibit  
Expression Of the OB-RGRP Protein  
And Method For Detecting Compounds  
Which Modify The Interaction Between  
Proteins Of the OB-RGRP Family and  
The Leptin Receptor**

I hereby certify that this correspondence is being  
deposited with the United States Postal Service as First  
Class Mail in an envelope addressed to Mail Stop  
Sequence, Commissioner for Patents, P.O. Box 1450,  
Alexandria, VA 22313-1450, on

Aug. 12, 2004  
Date of Deposit  
Debra Cougle  
Signature

**STATEMENT REGARDING CONTENT OF PAPER AND COMPUTER READABLE  
COPIES PURSUANT TO 37 C.F.R. 1.821 (f)**

Mail Stop  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

The undersigned states that the content of the nucleotide and/or amino acid sequences set forth in the "Sequence Listing" part of the enclosed patent application required by 37 C.F.R. 1.821 (c) and the computer readable copies required by 37 C.F.R. 1.821 (e) submitted herewith are the same.

Respectfully submitted,

F. Aaron Dubberley  
F. Aaron Dubberley, Reg. No. 41,001  
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, New Jersey 08807-0800  
Telephone (908) 231-3737  
Telefax (908) 231-2626

Aventis Docket No. FRAV2003/0005USNP